Li, Yi Ming
Zhang, Li Hui
Li, Xue Jun
Zhang, Bin
Hou, Jia Ning
Tong, Nan Wei
Clinical trials referenced in this document:
Documents that mention this clinical trial
2188-PUB: Efficacy and Safety in Chinese T2D Patients Discontinued from OAM to Once-Weekly Dulaglutide Monotherapy
https://doi.org/10.2337/db20-2188-pub
Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials
https://doi.org/10.1007/s13300-020-00869-z
2313-PUB: Efficacy by Baseline BMI with Once Weekly Dulaglutide in Chinese T2DM Patients
https://doi.org/10.2337/db19-2313-pub
Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1
https://doi.org/10.1007/s13300-020-00799-w
Funding for this research was provided by:
Lilly Suzhou Pharmaceutical Co. Ltd
Article History
Received: 6 January 2020
First Online: 26 March 2020